Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial

Subjects

Subjects :

medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
Adipokine
Inflammation
Type 2 diabetes
chemistry.chemical_compound
Endocrinology
Glucosides
Internal medicine
Internal Medicine
medicine
Humans
In patient
Obesity
Benzhydryl Compounds
Dapagliflozin
Adiposity
Adiponectin
business.industry
Atherosclerotic disease
General Medicine
medicine.disease
Diabetes Mellitus, Type 2
chemistry
medicine.symptom
business

Details

ISSN :

12623636

Volume :

48

Database :

OpenAIRE

Journal :

Diabetes & Metabolism

Accession number :

edsair.doi.dedup.....7ad51695c49cbe7f7ad356d8c3b329bd

Full Text :

https://doi.org/10.1016/j.diabet.2021.101304